The dynamics of medical care in skin cancers

The dynamics of medical care in skin cancers EDITORIAL URRENT PINION Reinhard Dummer Ten years ago, surgery was the only reliable treat- immunotherapies, or we can use other immune ment option in most skin cancers. Medical therapy modulators such as anti-tumor necrosis factor including chemotherapy was standard of care with- strategies earlier. out any benefit concerning overall survival. Moreover, we can search for additional combi- Many patients with advanced melanoma nation agents that are specifically selected for the individual patient, such as concept precision immu- received monochemotherapy with dacarbazine for metastatic disease. Others were treated with high- notherapy. With this, there is a good chance that dose interleukin 2. This treatment causes substantial the overall outcome of immunotherapy will be side-effects and many medical complications. improved. A new molecule in development is epa- In the adjuvant situation, high-dose interferon a cadostat, an IDO1 inhibitor that has demonstrated was used. Interferon a has an impact on the out- promising progression-free survival, as well as come, however, again this therapy was quiet toxic. a good response rate and favorable safety profile Many patients suffered for months from flu-like compared with current monotherapies. symptoms and some also from depression. On the Targeted therapies achieve response rates of basis of a http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Oncology Wolters Kluwer Health

The dynamics of medical care in skin cancers

Loading next page...
 
/lp/wolters_kluwer/the-dynamics-of-medical-care-in-skin-cancers-hpmfIr18BN
Publisher
Wolters Kluwer
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1040-8746
eISSN
1531-703X
D.O.I.
10.1097/CCO.0000000000000435
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL URRENT PINION Reinhard Dummer Ten years ago, surgery was the only reliable treat- immunotherapies, or we can use other immune ment option in most skin cancers. Medical therapy modulators such as anti-tumor necrosis factor including chemotherapy was standard of care with- strategies earlier. out any benefit concerning overall survival. Moreover, we can search for additional combi- Many patients with advanced melanoma nation agents that are specifically selected for the individual patient, such as concept precision immu- received monochemotherapy with dacarbazine for metastatic disease. Others were treated with high- notherapy. With this, there is a good chance that dose interleukin 2. This treatment causes substantial the overall outcome of immunotherapy will be side-effects and many medical complications. improved. A new molecule in development is epa- In the adjuvant situation, high-dose interferon a cadostat, an IDO1 inhibitor that has demonstrated was used. Interferon a has an impact on the out- promising progression-free survival, as well as come, however, again this therapy was quiet toxic. a good response rate and favorable safety profile Many patients suffered for months from flu-like compared with current monotherapies. symptoms and some also from depression. On the Targeted therapies achieve response rates of basis of a

Journal

Current Opinion in OncologyWolters Kluwer Health

Published: Mar 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off